A clinical trial of R-CHOP with antiretroviral therapy for newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphoma

A clinical trial of R-CHOP with antiretroviral therapy for newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphoma - R-CHOP and HAART for AIDS-related NHL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001452

Enrollment

Registered

2008-10-23

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphoma

Interventions

R-CHOP with HAART

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)HIV positive 2)Pathologically confirmed CD20-positive non-Hodgkin lymphoma 3)aged 20 to 64 4)ECOG performance status score 0-3 5)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Burkitt's lymphoma 2)CNS involvement 3)Uncontrolled opportunistic infections

Design outcomes

Primary

Measure	Time frame
The 2-year progression-free survival	—

Secondary

Measure	Time frame
The 2-year overall survival, remission rate, toxicity, and the incidence of opportunistic infections	—

Countries

Japan

Contacts

Public ContactJunko Tanuma

National Center for Global Health and Medicine AIDS Clinical Center

jtanuma@acc.ncgm.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026